Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2003

View Archived Issues

Good efficacy and long-term safety described for MT-100 in migraine

Commencement of phase II trial of Cop-1 for Huntington's disease

Guilford awarded grants totaling USD 5.7 million for several programs

Adolor announces positive results in phase III alvimopan study for postoperative ileus

Cardioprotective effects described for pexelizumab after acute myocardial infarction

Gemcabene improves lipid profile of patients with low serum HDL cholesterol levels

Duloxetine effective in improving anxiety associated with depression

No adverse effects reported for safinamide after tyramine challenge

Enhanced activity of novel paclitaxel analogues against drug-resistant breast cancer cells

Metabotropic glutamate receptor agonist as a nonsedative anxiolytic

Evaluation of a novel antiestrogen drug delivery system

FDA grants orphan drug designation for IDN-6556 in liver transplantation

Lorus and Cyclacel enter license agreement for NC-381

PhotoCure's Hexvix nearing approval in Europe

New cannabinoid CB2 ligands prepared and tested at Pharmos

Na+/H+ exchange inhibitors identified by Aventis researchers

Nippon Zoki claims novel tachykinin antagonists, their preparation and use

Novel sodium channel blockers covered by Boehringer Ingelheim patent

Selective MAO-B inhibitors with utility in Alzheimer's disease and senile dementia

New neuropeptide Y5 receptor antagonists described by Roche

Novartis presents new CB1 agonists for pain and other disorders

Toyama and Eisai submit NDA for antirheumatic drug T-614

Maxim completes enrollment for phase III trial of Ceplene with IL-2

Phase III hepatitis C trial of Zadaxin enrolled

Voltage-gated sodium channel blockers with preference for the inactivated state of the channel

Dual-target hybrid antibiotics designed at Microbiotix

OCID-0050, a new investigational oxazolidinone for resistant staphylococcal infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...